Literature DB >> 22049912

Mometasone furoate dry powder inhaler for the treatment of asthma.

Tracy B Fausnight1, Timothy J Craig.   

Abstract

INTRODUCTION: Asthma is a chronic inflammatory disease that causes significant morbidity and mortality. Inhaled corticosteroids are the preferred initial treatment for this disorder. Mometasone furoate dry powder is an inhaled corticosteroid that is approved for once-daily treatment of asthma in both adults and children as young as 4 years. AREAS COVERED: The goal of this paper is to review the clinical efficacy and safety of mometasone furoate dry powder inhaler for the treatment of asthma. A literature search using PubMed was done using the terms 'mometasone furoate', 'inhaled corticosteroid' and 'asthma', focusing on articles that highlighted clinical trials and addressed efficacy of the medication. EXPERT OPINION: Mometasone furoate dry powder inhaler has an excellent safety and efficacy profile. For patients with persistent asthma who require treatment with an inhaled corticosteroid, mometasone furoate is an excellent therapeutic choice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22049912     DOI: 10.1517/14656566.2011.630390

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

Review 1.  Mometasone furoate nasal spray: a systematic review.

Authors:  Desiderio Passali; Maria Carla Spinosi; Anna Crisanti; Luisa Maria Bellussi
Journal:  Multidiscip Respir Med       Date:  2016-05-02

Review 2.  The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials.

Authors:  Yanling Song; Kaiyu Pan; Yuyan Chen; Xiaoming Wang; Jun Tian
Journal:  Postepy Dermatol Alergol       Date:  2020-02-25       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.